Why the study?
Does ticlopidine and aspirin prevent stent thrombosis in Japanese patients after sirolimus-eluting stent implantation?
Does ticlopidine and aspirin prevent stent thrombosis in Japanese patients after sirolimus-eluting stent implantation?
Dual antiplatelet therapy with ticlopidine and aspirin is associated with a very low incidence of late and very late stent thrombosis in Japanese patients after sirolimus-eluting stent implantation.
Answers are grounded in this paper and cite their sources.
Low thrombosis rates with ticlopidine-aspirin post-SES in Japanese patients; hypothesis-generating and should not yet change practice.
BACKGROUND: There is little information about the efficacy of ticlopidine plus aspirin after sirolimus-eluting stent (SES) implantation. METHODS AND RESULTS: The incidence of stent thrombosis was evaluated in 1,029 patients receiving ticlopidine and aspirin after SES deployment. Clinical follow-up was obtained in 98.9% (mean follow-up 17.0+/-7.9 months). Early stent thrombosis was observed in 5 patients (0.49%). There was 1 case each of late (0.1%) and very late stent thrombosis (0.1%). CONCLUSION: Late and very late stent thrombosis in Japanese patients receiving ticlopidine and aspirin after SES deployment occurs infrequently.
No takes yet. Share an insight, caveat, or question.
Kitahara et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: